Phase II study of the safety and efficacy of temsirolimus in east asian patients with advanced renal cell carcinoma

Medicine and Dentistry

• Temsirolimus 100%
• Clear Cell Renal Cell Carcinoma 57%
• Adverse Event 28%
• Toxicity 14%
• Metastatic Carcinoma 14%
• Systemic Therapy 14%
• Metabolite 14%
• Rapamycin 14%
• Group Therapy 14%
• Anemia 14%
• Intention-to-Treat Analysis 14%
• Pneumonia 14%
• Hyperglycemia 14%
• Time to Treatment 14%
• Progression Free Survival 14%
• Mechanistic Target of Rapamycin 14%
• Response Evaluation Criteria in Solid Tumors 14%
• Hypophosphatemia 14%
• Stomatitis 14%
• Interstitial Lung Disease 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Temsirolimus 100%
• Renal Cell Carcinoma 57%
• Adverse Event 28%
• Metastasis 14%
• Toxicity 14%
• Rapamycin 14%
• Hyperglycemia 14%
• Pneumonia 14%
• Mammalian Target of Rapamycin 14%
• Progression Free Survival 14%
• Tolerability 14%
• Hypophosphatemia 14%
• Anemia 14%
• Stomatitis 14%
• Interstitial Lung Disease 14%

Agricultural and Biological Sciences

• Confidence Interval 100%
• Toxicity 25%
• Metabolite 25%
• Hyperglycemia 25%